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HABP = hospital-acquired bacterial pneumonia 
ICU = intensive care unit 
FDA = Food and Drug Administration  
PROPHETIC = Prospective Identification of Pneumonia in Hospitalized Patients in the Intensive 
Care Unit 
VABP = ventilator-associated bacterial pneumonia 
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Abstract 
Background: Pneumonia is the leading infection-related cause of death. Using simple clinical 
criteria and contemporary epidemiology to identify patients at high risk of nosocomial 
pneumonia should enhance prevention efforts and facilitate development of new treatments in 
clinical trials.  
Research Question: What are the clinical criteria and contemporary epidemiology trends 
helpful in identifying patients at high risk of nosocomial pneumonia?  
Study Design and Methods: Within the intensive care units of 28 United States hospitals, we 
conducted a prospective cohort study among adults hospitalized more than 48 hours and 
considered high risk for pneumonia (defined as treatment with invasive or noninvasive 
ventilatory support or high levels of supplemental oxygen). We estimated the proportion of high-
risk patients developing nosocomial pneumonia. Using multivariable logistic regression, we 
identified patient characteristics and treatment exposures associated with increased risk of 
pneumonia development during the intensive care unit admission. 
Results: Between February 6, 2016 and October 7, 2016, 4613 high-risk patients were enrolled. 
Among 1464/4613 (32%) high-risk patients treated for possible nosocomial pneumonia, 
537/1464 (37%) met the study pneumonia definition. Among high-risk patients, a multivariable 
logistic model was developed to identify key patient characteristics and treatment exposures 
associated with increased risk of nosocomial pneumonia development (c-statistic 0.709, 95% 
confidence interval 0.686 to 0.731). Key factors associated with increased odds of nosocomial 
pneumonia included an admission diagnosis of trauma or cerebrovascular accident, receipt of 
enteral nutrition, documented aspiration risk, and receipt of systemic antibacterials within the 
preceding 90 days. 
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Interpretation: Treatment for nosocomial pneumonia is common among intensive care unit 
patients receiving high levels of respiratory support, yet more than half of patients treated do not 
fulfill standard diagnostic criteria for pneumonia. Application of simple clinical criteria may 
improve the feasibility of clinical trials of pneumonia prevention and treatment by facilitating 
prospective identification of patients at highest risk. 
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Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia 
(VABP) are the most common nosocomial infections and the leading reasons for antibiotic 
prescriptions in the intensive care unit (ICU).1,2 HABP/VABP development is associated with 
high mortality and substantial short- and long-term morbidity.3,4 Delayed effective antimicrobial 
therapy is associated with worse outcomes, so clinicians are compelled to treat promptly when 
HABP/VABP is suspected. Nevertheless, diagnosing HABP/VABP is inexact because diagnosis 
is based on a constellation of symptoms and clinical signs that are not sufficiently predictive of 
pneumonia.5–7 HABP/VABP management is further complicated by frequent infection with 
multidrug resistant pathogens, few available antibiotics with demonstrated efficacy in 
HABP/VABP treatment, and a limited pipeline of new antibiotics undergoing evaluation in 
clinical trials.8,9   
The low level of HABP/VABP antimicrobial development is a multifaceted problem 
driven in part by poor clinical trial feasibility, due to low enrollment.10–12 Poor enrollment itself 
is a complex issue in which the relative contributions of changing HABP/VABP prevalence and 
high screening failure rates are unknown. Estimates of HABP/VABP prevalence are highly 
variable because consensus definitions are lacking and there is variability in interpretation of 
some criteria, such as the chest radiograph.13 Epidemiologic definitions of HABP/VABP likely 
underestimate the true frequency of antibiotic prescribing for suspected nosocomial pneumonia 
in modern clinical practice. Furthermore, historical estimates of HABP/VABP burden may not 
capture the impact of recent VABP prevention efforts and implementation of ventilator-
associated event monitoring and reporting.14,15  
Improved understanding of contemporary HABP/VABP incidence using a definition 
employed in clinical trials may inform the design of more feasible trials. Evaluating risk for 
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HABP/VABP associated with patient characteristics and treatment exposures may help identify 
those patients at highest risk for disease acquisition, ultimately promoting the study of new 
treatments and prevention efforts by facilitating the conduct of efficient clinical studies focused 
on the patients most likely to benefit, while decreasing harm in those less likely to benefit.16   
Using a large multicenter cohort of prospectively identified patients and a standard 
definition of HABP/VABP outlined in United States Food and Drug Administration (FDA) draft 
guidance to industry,17 the Clinical Trials Transformation Initiative HABP/VABP studies team 
designed the Prospective Identification of Pneumonia in Hospitalized Patients in the ICU 
(PROPHETIC) study, which: 1) defined the contemporary incidence of HABP/VABP among 
patients at high-risk for this infection; and 2) identified demographic factors, comorbid 
conditions, and treatment exposures associated with increased risk of HABP/VABP development 
during ICU admission. 
 
Methods 
Study Design 
We conducted a multicenter, prospective, observational cohort study in ICUs of 28 United States 
hospitals. Enrolling sites comprised a diverse group of both community and tertiary academic 
medical centers with a median size of 727 (range 252, 1394) inpatient beds. All eligible adults 
admitted to participating ICUs were screened for the presence of predefined risk factors for 
HABP/VABP development (eFigure 1). Patients considered high risk for HABP/VABP 
development (defined as receiving invasive mechanical ventilation, noninvasive ventilation, or 
treatment with at least 50% fraction of inspired supplemental oxygen via high-flow, high-
humidity nasal cannula, aerosol mask, partial or non-rebreather mask for a minimum of 12 hours 
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within any 24-hour period in the preceding 7 days) were enrolled and prospectively followed for 
development of signs or symptoms of possible pneumonia throughout their ICU course (study 
definitions are provided in the Supplementary Methods).  
Adults ≥18 years old admitted to participating ICUs were eligible for enrollment if 
hospitalized for >48 hours or within 7 days of discharge from acute or chronic care facilities.  
Patients were excluded if pregnant or currently breastfeeding, currently receiving treatment for 
lung cancer or metastatic cancers with lung involvement, receiving comfort measures only, or 
previously treated for suspected pneumonia while enrolled in the study. The study protocol was 
approved and a waiver of informed consent was granted by Copernicus Group, an independent 
review board (CTTI_001, DCR2-15-710), or the institutional review board of the participating 
institution, when required. 
Baseline demographics and treatment exposures were recorded for all patients at 
enrollment. High-risk patients were followed daily for development of clinical signs or 
symptoms of possible pneumonia or receipt of antibiotics to treat possible pneumonia. Antibiotic 
exposures and results of clinically obtained microbiologic testing were recorded for all patients 
receiving antibiotics for possible pneumonia.  
 
Definitions 
The high-risk population was defined as patients receiving high levels of respiratory support, but 
lacking study diagnostic criteria for pneumonia at the time of enrollment. The treated population 
was defined as the subset of high-risk patients receiving antibiotics for possible pneumonia, 
defined by documentation of antibiotic indications for pneumonia or undifferentiated sepsis for 
which pneumonia was considered a possible cause in the medical record, during their ICU 
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course. The HABP/VABP population included only the subset of treated patients fulfilling the 
study HABP/VABP definition, which required at least one criterion to be present from each 
diagnostic domain including radiographic criteria, respiratory signs and symptoms, systemic 
inflammation, and timing of symptom onset. The study HABP/VABP definition was consistent 
with that used in treatment guidelines and developed from inclusion criteria in antibacterial drug 
treatment trials for HABP/VABP outlined in FDA draft guidance for industry (full study 
definitions are provided in the Supplementary Methods).3,17 
 
Microbiologic Testing 
Clinically obtained microbiologic testing results were recorded in the case report form. No 
specific microbiologic testing or procedures were mandated by the study protocol. For positive 
microbiologic results, the organism name and reported antibiotic susceptibilities were recorded.  
Extended spectrum beta-lactamase production was captured when identified by each site’s 
standard reporting protocol. 
 
Outcomes 
The primary outcome was the rate of study-defined HABP/VABP diagnosis in ICU patients 
meeting the predetermined high-risk criteria. The key secondary outcome was determination of 
risk factors associated with HABP/VABP development in ICU patients meeting prespecified 
high-risk criteria. 
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Statistical Analysis 
All analyses were performed in predefined study populations. Patient characteristics were 
summarized as frequency and percentages for categorical variables, and medians with 25th and 
75th percentiles for continuous variables. The cumulative percentage of patients developing 
VABP or HABP before study completion (due ICU discharge, transition to comfort measures, or 
death) was graphed as a function of time since high risk criteria were met. We performed risk 
modeling using multivariable logistic regression models and assessed relationships between 38 
baseline risk factors and HABP/VABP development.  
The aim of developing the multivariable logistic regression model was to identify patient 
characteristics and treatment exposures associated with increased risk for HABP/VABP 
development during the ICU course at the time the patient might be screened for enrollment in a 
HABP/VABP clinical trial. Patients who met the study definition of HABP/VABP at the time of 
enrollment were excluded from the model. Final predictors were identified using clinical 
guidance and a backward variable selection process at the 0.1 level of significance for model 
retention. These predictors were confirmed independently using a forward variable selection 
process. Collinearity was assessed by calculating the phi coefficient between prespecified 
covariates identified by clinical guidance as most likely to be associated. In a sensitivity analysis, 
we evaluated whether these predictors were also associated specifically with development of 
VABP, among the subset of high-risk patients receiving >48 hours of invasive mechanical 
ventilation. Discriminatory capacity of the multivariable models was assessed using the c-
statistic. Calibration for each model was assessed graphically to display the level of agreement 
between observed and predicted rates of HABP/VABP and VABP respectively, by decile of risk. 
The out-of-sample performance of each model was evaluated using internal validation by 
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estimating the optimism-corrected c-statistic using 200 bootstrap samples. All analyses were 
performed using SAS version 9.4.  
 
Results 
Between February 6, 2016 and October 7, 2016, the study enrolled 5756 ICU patients; 4613 
(80%) had high-risk factors for HABP/VABP development at enrollment and met study 
inclusion/exclusion criteria (Figure 1). Of the 4613 enrolled high-risk patients, 537 (12%) met 
the study HABP/VABP definition over a median follow-up of 7 days (Figure 2). Among 
1464/4613 (32%) high-risk patients treated for possible pneumonia during their ICU course, 
927/1464 patients, comprising 63% of the treated population, did not fulfill at least one domain 
of HABP/VABP diagnostic inclusion criteria recommended in FDA draft guidance (eTable 1). 
Of 1464 treated high-risk patients, 1181 (81%) were prescribed antibiotics for an indication of 
pneumonia and 523/1181 (44%) met the study HABP/VABP definition. Among 283/1464 (19%) 
high-risk patients treated with antibiotics for an indication of undifferentiated sepsis (for which 
pneumonia was being evaluated as a potential etiology) or for which no antibiotic indication was 
recorded, 14 (5%) met the study HABP/VABP definition.  
Characteristics were similar of high-risk, treated, HABP, and VABP populations, 
including age, ICU type, hospital and ICU length-of-stay, and type of respiratory support (Table 
1). In the HABP/VABP population, 502/537 (93%) patients were receiving invasive mechanical 
ventilation at the time of pneumonia diagnosis, including 108/537 (20%) patients with ventilated 
HABP (<48 hours of invasive mechanical ventilation at time of diagnosis) and 394/537 (73%) 
with VABP. The median duration of mechanical ventilation for high-risk patients that 
subsequently developed VABP was 8 days (interquartile range, 5–14) (Figure 3).   
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The multivariable logistic regression model was developed using 4613 high-risk patients. 
Key patient characteristics and treatment exposures associated with increased odds of pneumonia 
(meeting the study HABP/VABP definition) included an ICU admission diagnosis of trauma or 
cerebrovascular accident, receipt of enteral nutrition, documented aspiration risk, and receipt of 
systemic antibacterials within the preceding 90 days (Table 2). Collinearity that would impact 
stability of the multivariable model was not identified. The HABP/VABP logistic regression 
model demonstrated moderate discriminatory capacity and calibration (c-statistic 0.709 [0.686, 
0.731]) (eFigure 2). The multivariable model yielded out-of-sample discrimination with an 
optimism-corrected c-statistic of 0.693 [0.670, 0.715]. The multivariable model was also 
evaluated in 3712/4613 (80%) patients at high risk for developing VABP (exposure to invasive 
mechanical ventilation >48 hours) and demonstrated similar discriminatory capacity and 
calibration (c-statistic 0.698 [0.671, 0.726], optimism-corrected c-statistic 0.677 [0.650, 0.705]) 
(eTable 2) (eFigure 3). 
Microbiologic testing was collected and recorded in 477/537 (89%) patients fulfilling 
study HABP/VABP criteria. A bacterial pathogen was identified from at least one source in 
306/477 (64%) of tested patients (eFigures 4 and 5). Staphylococcus aureus (102/477 [21%] 
patients) and Pseudomonas aeruginosa (52/477 [11%] patients) were the most frequently 
isolated bacterial pathogens among tested HABP/VABP patients (eFigures 6 and 7). 
Enterobacteriaceae were identified in 116/477 (24%) tested HABP/VABP patients. Extended 
spectrum beta-lactamase-producing bacteria were reported in 13/477 (3%) and carbapenem-
resistant organisms in 3/477 (<1%) tested HABP/VABP patients.   
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Discussion 
This large, contemporary, prospective cohort study made two pivotal observations. First, 
treatment for nosocomial pneumonia is common; 32% of prospectively identified high-risk 
patients received antibiotics for possible HABP/VABP, and 12% of these high-risk patients met 
case definitions for HABP/VABP consistent with FDA draft guidance for sponsors conducting 
interventional trials.17 Second, we were able to identify common patient characteristics and 
treatment exposures associated with increased odds of HABP/VABP development among 
prospectively identified high-risk patients. Identification of these risk associations, in 
combination with the high-risk criteria we employed in this study, may help focus future 
prevention efforts, inform the design of more efficient clinical trials, and facilitate innovative 
enrollment strategies such as early screening or consent of patients at high-risk for developing 
HABP/VABP. 
Since this study was developed to inform design of more efficient clinical trials, we used 
a HABP/VABP definition consistent with recommended clinical trial inclusion criteria in FDA 
draft guidance.17 Although national surveillance data suggest a decreasing incidence of 
nosocomial pneumonia, this study demonstrates HABP and VABP remain common nosocomial 
infections.18 The higher rates of pneumonia observed in this study may be partially due to using a 
HABP/VABP definition similar to that recommended in clinical practice guidelines, rather than 
an epidemiologic definition.3,19,20 To minimize risk of underestimating HABP/VABP among 
high-risk patients treated with antibiotics for unclear indications, we included patients prescribed 
antibiotics for undifferentiated sepsis if pneumonia was considered a possible cause. Even if 
high-risk patients treated with antibiotics for a clinical indication of undifferentiated sepsis were 
excluded, 26% of the high-risk population was treated with antibiotics for a clinical indication of 
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pneumonia and only 44% of these patients ultimately met the study HABP/VABP definition; this 
discrepancy highlights diagnostic uncertainty in the management of HABP/VABP, as well as the 
urgent need for new tools to improve the accuracy and consistency of HABP/VABP 
diagnosis.13,21  
Discordance between treatment and diagnostic confirmation may reflect clinicians’ 
reluctance to base treatment decisions upon imprecise chest radiography, insensitive 
HABP/VABP diagnostic criteria, or variability within treatment practices.22–24 Though 
impossible to confidently evaluate within the design of this study, the frequency of antibiotic 
prescribing for clinical syndromes not fulfilling the study HABP/VABP definition also raises 
concern for antibiotic overprescription in this high-risk population. Such concerns emphasize the 
need for prospective evaluation of patient-centered outcomes associated with antibacterial 
exposure in the management of suspected HABP/VABP using criteria of increasing stringency, 
particularly since receiving antibiotics is itself a risk factor for developing pneumonia, carries 
risk of adverse events, and may preclude eligibility for HABP/VABP trial enrollment.25 
Nevertheless, this study does provide evidence that ICU patients receiving high levels of 
respiratory support do frequently receive antibiotics for HABP/VABP and fulfill recommended 
inclusion criteria for enrollment in antibacterial drug trials.  
A key result of this study was identification of common patient characteristics and 
treatment exposures associated with increased odds of HABP/VABP development. Our model 
identified several clinical characteristics and potentially modifiable risk factors (receipt of 
systemic antibacterials within the preceding 90 days or antacid medications during the current 
hospitalization) previously associated with increased odds of HABP/VABP.26–29 The findings 
from this large prospective cohort validate previous risk associations and may also inform future 
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development of a more comprehensive HABP/VABP risk prediction tool used to design efficient 
clinical trial enrollment strategies or effectively steward costly or higher-risk prevention 
strategies that cannot be practically or safely implemented universally. Development of a 
comprehensive risk prediction tool could complement real-time monitoring systems to 
effectively identify patients developing nosocomial pneumonia as early and efficiently as 
possible.30 Prospective identification of patients at high-risk for HABP/VABP, using the high-
risk criteria employed in this study, potentially enhanced by more comprehensive risk prediction 
tools, may also help focus clinical trial screening efforts on patients at highest risk, facilitating 
enrollment in more efficient clinical trials and furthering evaluation of early informed consent 
trial designs whereby patients or their surrogates may be approached about enrollment in 
HABP/VABP clinical trials before developing nosocomial pneumonia.31  
 
Limitations 
This study has some limitations. First, since only United States adult ICUs were included, our 
study may not be generalizable to other populations; therefore, our findings have been evaluated 
in a pediatric ICU cohort, and analysis of data from a European cohort is ongoing.32 Second, 
candidate risk factors for HABP/VABP were only evaluated in patients meeting prespecified 
high-risk criteria, so odds of pneumonia could not be evaluated in patients who did not receive 
high levels of respiratory support and were presumably at lower risk for developing 
HABP/VABP. Third, since this study was only conducted in ICU patients, 85% of whom 
received invasive mechanical ventilation during their ICU course, nonventilated HABP is 
underrepresented. Epidemiologic studies suggest HABP is increasingly common and accounts 
for the majority of nosocomial pneumonias.33,34 The clinical characteristics and treatment 
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exposures associated with increased odds of HABP/VABP in our study may not have similar 
associations with nonventilated HABP, especially HABP that develops outside the ICU setting. 
Since this study was developed to inform design of efficient HABP/VABP clinical trials in the 
ICU setting, we evaluated risk associated with a combined HABP/VABP endpoint. We did not 
observe significant differences in the prevalence of candidate risk factors between HABP and 
VABP populations or in performance of the multivariable model when evaluating only the 
subgroup of high-risk patients at risk for VABP, but this does not diminish the fact that HABP 
and VABP are distinct clinical entities and an evaluation of risk factors for nonventilated HABP 
would require a broader inclusion of hospitalized patients outside the ICU. Fourth, because some 
variables required to calculate standard severity of illness scores were not collected upon study 
enrollment, we could not include these patient characteristics in the multivariable model. Finally, 
although the proportion of cases with a bacterial pathogen detected (64%) was consistent with 
prior studies, we could not accurately estimate the burden of nosocomial pneumonia associated 
with viral pathogens, which have been associated with nosocomial pneumonia in several single-
center studies.8,35,36   
 
Interpretation 
In conclusion, the burden of HABP and VABP among critically ill patients is substantial. 
Treatment for possible nosocomial pneumonia is exceedingly common among patients receiving 
high levels of respiratory support, yet most of these patients do not fulfill standard clinical 
definitions of HABP/VABP. Prospective identification of patients at high-risk for HABP/VABP 
using simple clinical criteria may facilitate conduct of innovative and efficient clinical trials to 
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promote development of optimal preventive, diagnostic, and treatment strategies to improve 
management of this disease.   
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Table 1. Characteristics of Key Study Populations 
Characteristic High-Risk 
Patients 
(N=4613) 
Treated Patients 
(N=1464) 
HABP Patients 
(N=143) 
VABP Patients 
(N=394) 
Demographicsa      
   Age, median (IQR), y 61.0 (50.0, 70.0) 60.0 (49.0, 70.0) 63.0 (55.0, 74.0) 58.0 (45.0, 69.0) 
   Female sex, No. (%) 2058 (44.6) 599 (40.9) 51 (35.7) 159 (40.4) 
   Body mass index, median (IQR), kg/m2 28.9 (24.1, 35.0) 28.5 (23.8, 34.8) 26.1 (22.1, 31.6) 29.4 (25.1, 35.1) 
Hospital length of stay, median (IQR), days 4.0 (3.0, 8.0) 5.0 (3.0, 9.0) 6.0 (3.0, 10.0) 5.0 (3.0, 9.0) 
ICU length of stay, median (IQR), days 3.0 (2.0, 5.0) 4.0 (2.0, 6.0) 4.0 (2.0, 7.0) 3.5 (2.0, 6.0) 
APACHE II Score, b median (IQR)    19.0 (15.0, 27.0) 23.0 (17.0, 28.0) 
Treatment Exposures, c No. (%)      
   Invasive mechanical ventilation 3908 (84.7) 1316 (89.9) 108 (75.5) 394 (100) 
   Noninvasive mechanical ventilation 751 (16.3) 258 (17.6) 36 (25.2) 42 (10.7) 
   Enteral nutrition 3035 (65.8) 1149 (78.5) 98 (68.5) 357 (90.6) 
   Vasopressor/inotropic therapy 2211 (47.9) 722 (49.3) 70 (49.0) 226 (57.4) 
   Biologic agents, current hospitalization 169 (3.7) 57 (3.9) 3 (2.1) 21 (5.3) 
   Corticosteroids, current hospitalization 589 (12.8) 226 (15.4) 32 (22.4) 54 (13.7) 
   PPI/H-2 blocker, current hospitalization 3475 (75.3) 1185 (80.9) 114 (79.7) 332 (84.3) 
   Blood product transfusion, prior 7 days 1062 (23.0) 332 (22.7) 33 (23.1) 132 (33.5) 
   Systemic antibacterials, prior 90 days 2832 (61.4) 1020 (69.7) 108 (75.5) 275 (69.8) 
   Mechanical circulatory support 220 (4.8) 69 (4.7) 4 (2.8) 29 (7.4) 
   Massive volume resuscitation 532 (11.5) 174 (11.9) 12 (8.4) 61 (15.5) 
Active Medical Problems,c,d No. (%)      
   Acute respiratory distress syndrome 686 (14.9) 332 (22.7) 36 (25.2) 66 (16.8) 
   Acute kidney injury 1078 (23.4) 410 (28.0) 32 (22.4) 88 (22.3) 
   Chronic kidney disease 541 (11.7) 173 (11.8) 13 (9.1) 45 (11.4) 
   End stage renal disease 270 (5.9) 70 (4.8) 8 (5.6) 15 (3.8) 
   Aspiration risk 605 (13.1) 325 (22.2) 31 (21.7) 100 (25.4) 
   Autoimmune disorder 194 (4.2) 68 (4.6) 7 (4.9) 21 (5.3) 
   Chemotherapy, prior 30 days 139 (3.0) 55 (3.8) 7 (4.9) 13 (3.3) 
   Diabetes mellitus 1304 (28.3) 393 (26.8) 24 (16.8) 91 (23.1) 
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Characteristic High-Risk 
Patients 
(N=4613) 
Treated Patients 
(N=1464) 
HABP Patients 
(N=143) 
VABP Patients 
(N=394) 
   Immunocompromised 545 (11.8) 170 (11.6) 23 (16.1) 38 (9.6) 
   Chronic respiratory failure 129 (2.8) 39 (2.7) 4 (2.8) 10 (2.5) 
   Congestive heart failure, NYHA class IV 141 (3.3) 41 (3.1) 3 (2.4) 6 (1.7) 
   Cirrhosis or gastrointestinal bleeding 467 (10.1) 150 (10.2) 16 (11.2) 40 (10.2) 
   Cerebrovascular accident 400 (8.7) 162 (11.1) 14 (9.8) 46 (11.7) 
   Substance abuse 1289 (27.9) 422 (28.8) 34 (23.8) 115 (29.2) 
   HIV infection 54 (1.2) 10 (0.7) 2 (1.4) 3 (0.8) 
   Delirium or altered mental status 1276 (27.7) 455 (31.1) 40 (28.0) 112 (28.4) 
   Seizures 417 (9.0) 163 (11.1) 6 (4.2) 42 (10.7) 
   Chronic obstructive pulmonary disease 804 (17.4) 262 (17.9) 25 (17.5) 52 (13.2) 
   Myocardial infarction 337 (7.3) 115 (7.9) 11 (7.7) 24 (6.1) 
   Chronic dialysis (any type) 490 (10.6) 145 (9.9) 14 (9.8) 35 (8.9) 
Intensive care unit type, No. (%)     
Medical 2468 (53.5) 837 (57.2) 84 (58.7) 188 (47.7) 
Surgical/trauma 852 (18.5) 215 (14.7) 22 (15.4) 97 (24.6) 
Cardiac/cardiac surgery 769 (16.7) 194 (13.3) 18 (12.6) 50 (12.7) 
Neurosciences 350 (7.6) 139 (9.5) 9 (6.3) 42 (10.7) 
Mixed 174 (3.8) 79 (5.4) 10 (7.0) 17 (4.3) 
Intensive care admission source, No. (%)     
Emergency department 2729 (59.2) 926 (63.3) 97 (67.8) 225 (57.1) 
Skilled nursing, long term acute care 177 (3.8) 69 (4.7) 11 (7.7) 18 (4.6) 
Scheduled procedure 488 (10.6) 79 (5.4) 8 (5.6) 26 (6.6) 
Non-procedure; clinic or direct admission 812 (17.6) 282 (19.3) 18 (12.6) 83 (21.1) 
Other 407 (8.8) 108 (7.4) 9 (6.3) 42 (10.7) 
Intensive care admission diagnosis, No. (%)     
Acute hypercapnic respiratory failure 233 (5.1) 77 (5.3) 4 (2.8) 13 (3.3) 
Acute hypoxemic respiratory failure 893 (19.4) 348 (23.8) 40 (28.0) 69 (17.5) 
Acute myocardial infarction 124 (2.7) 41 (2.8) 6 (4.2) 7 (1.8) 
Acute renal failure or severe electrolyte 
abnormality 
45 (1.0) 12 (0.8) 1 (0.7) 2 (0.5) 
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Characteristic High-Risk 
Patients 
(N=4613) 
Treated Patients 
(N=1464) 
HABP Patients 
(N=143) 
VABP Patients 
(N=394) 
Altered mental status 337 (7.3) 118 (8.1) 10 (7.0) 23 (5.8) 
Cardiogenic shock 86 (1.9) 32 (2.2) 2 (1.4) 11 (2.8) 
Cerebrovascular accident 191 (4.1) 70 (4.8) 7 (4.9) 23 (5.8) 
Hemorrhagic shock or severe hemorrhage 94 (2.0) 27 (1.8) 0 (0.0) 11 (2.8) 
Other hypovolemic shock 17 (0.4) 3 (0.2) 1 (0.7) 1 (0.3) 
Planned post-operative ICU admission 475 (10.3) 82 (5.6) 9 (6.3) 32 (8.1) 
Sepsis or septic shock 337 (7.3) 99 (6.8) 12 (8.4) 23 (5.8) 
Shock 41 (0.9) 11 (0.8) 1 (0.7) 3 (0.8) 
Frequent/refractory seizures 94 (2.0) 39 (2.7) 1 (0.7) 14 (3.6) 
Trauma 275 (6.0) 101 (6.9) 10 (7.0) 60 (15.2) 
Other 1371 (29.7) 404 (27.6) 39 (27.3) 102 (25.9) 
Abbreviations: APACHE = acute physiology and chronic health evaluation; H2 = histamine blocker; HABP = hospital-
acquired bacterial pneumonia; ICU = intensive care unit; IQR = interquartile range; PPI = proton pump inhibitor; VABP = 
ventilator-associated bacterial pneumonia 
aCharacteristics recorded at the time of high-risk population enrollment.   
bSome variables required for APACHE II score calculation were only recorded when pneumonia diagnosis confirmed 
cCharacteristics recorded when pneumonia diagnosis confirmed or upon ICU discharge (for patients not developing 
HABP/VABP). 
dDiagnoses included in the active medical problem categories defined in supplement. 
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Table 2. High-Risk Patient Characteristic and Treatment Exposure Associations with Pneumonia Development 
 
Factor Type 3 
Wald Chi-Square 
Beta  
Coefficient 
Adjusted 
Odds Ratio 
(95% CI) 
P-Value 
ICU admission diagnosis 53.10    
   Acute hypercapnic respiratory failure  -0.31 0.73 (0.38, 1.39) 0.336 
   Acute hypoxemic respiratory failure  0.13 1.14 (0.74, 1.76) 0.552 
   Acute myocardial infarction  0.12 1.12 (0.55, 2.28) 0.749 
   Altered mental status or seizures  -0.06 0.94 (0.57, 1.55) 0.815 
   Cerebrovascular accident  0.51 1.67 (0.95, 2.94) 0.073 
   Sepsis or septic shock  -0.12 0.88 (0.52, 1.49) 0.646 
   Trauma  1.16 3.19 (1.96, 5.20) <.001 
   Shock (excluding septic shock)  0.06 1.06 (0.62, 1.83) 0.822 
   Other  0.10 1.11 (0.73, 1.68) 0.629 
   Planned post-operative ICU admission   reference  
Enteral nutrition 41.26 0.87 2.38 (1.83, 3.11) <.001 
Aspiration risk 39.18 0.74 2.10 (1.66, 2.65) <.001 
Systemic antibacterials within 90 days 16.78 0.44 1.56 (1.26, 1.92) <.001 
Admission source 13.53    
   Skilled nursing, long term acute care  0.60 1.82 (1.17, 2.82) 0.007 
   Non-procedure; clinic or direct admission  0.19 1.20 (0.93, 1.55) 0.152 
   Scheduled procedure  -0.37 0.69 (0.45, 1.06) 0.089 
   Other  0.14 1.15 (0.83, 1.61) 0.396 
   Emergency department   reference  
Diabetes mellitus 6.44 -0.29 0.75 (0.59, 0.94) 0.011 
Invasive mechanical ventilation 5.96 0.49 1.63 (1.10, 2.40) 0.015 
Noninvasive mechanical ventilation 4.57 0.30 1.35 (1.03, 1.78) 0.032 
Proton pump inhibitor therapy/H2-blocker therapy 4.36 0.27 1.30 (1.02, 1.67) 0.037 
Blood product transfusion in the last 7 days 3.80 0.21 1.24 (1.00, 1.53) 0.051 
Corticosteroids at current hospitalization 2.96 0.23 1.26 (0.97, 1.65) 0.086 
Female sex 2.70 -0.16 0.85 (0.70, 1.03) 0.101 
ICU length of stay (days), per 1-day increase 2.31 0.01 1.01 (1.00, 1.03) 0.128 
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Abbreviations: CI = confidence interval; ICU = intensive care unit; OR = odds ratio 
Characteristics and treatment exposures recorded at time of high-risk population enrollment.  
4613 patients included in analysis.   
Risk factors selected using backward selection with α=0.1 for model inclusion and clinical expertise.  
C-statistic: 0.709 (0.686, 0.731) 
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Figure Legends 
Figure 1. Patients at Risk for Nosocomial Pneumonia  
Screening, eligibility, and enrollment of patients at risk for nosocomial pneumonia. 
Abbreviations: HABP, hospital-acquired bacterial pneumonia; VABP, ventilator-associated 
bacterial pneumonia; ICU, intensive care unit 
 
Figure 2. Study Outcome for High-Risk Patients 
Of 4613 enrolled high-risk patients, 1464 (32%) were treated for possible pneumonia during 
their ICU course; of these, 537/1464 (37%) met the study HABP/VABP definition over a median 
follow-up of 7 days. 
Abbreviations: HABP, hospital-acquired bacterial pneumonia; VABP, ventilator-associated 
bacterial pneumonia; ICU, intensive care unit 
 
Figure 3. Cumulative Incidence of Nosocomial Pneumonia for High-Risk Patients 
Abbreviations: HABP, hospital-acquired bacterial pneumonia; VABP, ventilator-associated 
bacterial pneumonia 
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